Three lesions needed for MRI diagnosis of MS

A European expert group has proposed several revisions to the 2010 McDonald criteria for the use of MRI in diagnosing multiple sclerosis.

The MAGNIMS collaborative research network argued that new data on the application of MRI, as well as improvements in MRI technology, demanded changes to the multiple sclerosis (MS) diagnostic criteria.

The first proposed recommendation is that three or more focal lesions, rather than a single lesion, should be present to diagnose the involvement of the periventricular region and to show disease dissemination in space (Lancet Neurol. 2016 Jan 25. doi: 10.1016/S1474-4422[15]00393-2).

HUNG KUO CHUN/Thinkstock

“A single lesion was deemed not sufficiently specific to determine whether involvement of the periventricular region is due to a demyelinating inflammatory event, and the use of one periventricular lesion for assessing dissemination in space has never been formally validated,” wrote Dr. Massimo Filippi of Vita-Salute San Raffaele University, Milan, and his coauthors.

They also pointed out that incidental periventricular lesions can be found in up to 30% of patients with migraine, and in individuals with other neurologic disorders.

In addition, the group recommended that optic nerve lesions be added to the criteria for dissemination in space.

“Clinical documentation of optic nerve atrophy or pallor, neurophysiological confirmation of optic nerve dysfunction (slowed conduction), or imaging features of clinically silent optic nerve inflammation (MRI lesions or retinal nerve fiber layer thinning) support dissemination in space and, in patients without concurrent visual symptoms, dissemination in time.”

According to the new recommendations, disease dissemination in space can be shown by the involvement of at least two areas from a list of five possibilities: three or more periventricular lesions, one or more infratentorial lesions, one or more spinal cord lesions, one or more optic nerve lesions, or one or more cortical or juxtacortical lesions.

However, the group did not propose any significant changes to the criteria for dissemination in time, other than saying that the presence of nonenhancing black holes should not be considered as a potential alternative criterion to show dissemination in time in adult patients.

The committee also backed the existing recommendations that children aged 11 years or older with nonacute disseminated encephalomyelitis–like presentation should be diagnosed with the same criteria as adults, for dissemination in time and space.

“Several studies have confirmed that the 2010 McDonald criteria perform better than or similar to previously proposed pediatric MS criteria for diagnosis of children with nonacute disseminated encephalomyelitis presentations and pediatric patients older than 11 years, and the consensus group therefore recommend caution when using these criteria in children younger than 11 years,” they wrote.

Other recommendations include that there be no distinction required between symptomatic and asymptomatic MRI lesions for diagnosing dissemination in time or space; that the whole spinal cord be imaged to define dissemination in space, particularly in patients who do not fulfill the brain MRI criteria; and that the same criteria for dissemination in space be used for both primary progressive MS and relapse-onset MS, with cerebrospinal fluid results considered for clinically uncertain cases of primary progressive MS.

The expenses of the workshop where the recommendations were formulated were supported by an unrestricted educational grant from Novartis. The authors of the paper declared grants, consultancies, speaking fees, travel support, and honoraria from numerous pharmaceutical companies, including Novartis.

A European expert group has proposed several revisions to the 2010 McDonald criteria for the use of MRI in diagnosing multiple sclerosis.

The MAGNIMS collaborative research network argued that new data on the application of MRI, as well as improvements in MRI technology, demanded changes to the multiple sclerosis (MS) diagnostic criteria.

The first proposed recommendation is that three or more focal lesions, rather than a single lesion, should be present to diagnose the involvement of the periventricular region and to show disease dissemination in space (Lancet Neurol. 2016 Jan 25. doi: 10.1016/S1474-4422[15]00393-2).

HUNG KUO CHUN/Thinkstock

“A single lesion was deemed not sufficiently specific to determine whether involvement of the periventricular region is due to a demyelinating inflammatory event, and the use of one periventricular lesion for assessing dissemination in space has never been formally validated,” wrote Dr. Massimo Filippi of Vita-Salute San Raffaele University, Milan, and his coauthors.

They also pointed out that incidental periventricular lesions can be found in up to 30% of patients with migraine, and in individuals with other neurologic disorders.

In addition, the group recommended that optic nerve lesions be added to the criteria for dissemination in space.

“Clinical documentation of optic nerve atrophy or pallor, neurophysiological confirmation of optic nerve dysfunction (slowed conduction), or imaging features of clinically silent optic nerve inflammation (MRI lesions or retinal nerve fiber layer thinning) support dissemination in space and, in patients without concurrent visual symptoms, dissemination in time.”

According to the new recommendations, disease dissemination in space can be shown by the involvement of at least two areas from a list of five possibilities: three or more periventricular lesions, one or more infratentorial lesions, one or more spinal cord lesions, one or more optic nerve lesions, or one or more cortical or juxtacortical lesions.

However, the group did not propose any significant changes to the criteria for dissemination in time, other than saying that the presence of nonenhancing black holes should not be considered as a potential alternative criterion to show dissemination in time in adult patients.

The committee also backed the existing recommendations that children aged 11 years or older with nonacute disseminated encephalomyelitis–like presentation should be diagnosed with the same criteria as adults, for dissemination in time and space.

“Several studies have confirmed that the 2010 McDonald criteria perform better than or similar to previously proposed pediatric MS criteria for diagnosis of children with nonacute disseminated encephalomyelitis presentations and pediatric patients older than 11 years, and the consensus group therefore recommend caution when using these criteria in children younger than 11 years,” they wrote.

Other recommendations include that there be no distinction required between symptomatic and asymptomatic MRI lesions for diagnosing dissemination in time or space; that the whole spinal cord be imaged to define dissemination in space, particularly in patients who do not fulfill the brain MRI criteria; and that the same criteria for dissemination in space be used for both primary progressive MS and relapse-onset MS, with cerebrospinal fluid results considered for clinically uncertain cases of primary progressive MS.

The expenses of the workshop where the recommendations were formulated were supported by an unrestricted educational grant from Novartis. The authors of the paper declared grants, consultancies, speaking fees, travel support, and honoraria from numerous pharmaceutical companies, including Novartis.

A European expert group has proposed several revisions to the 2010 McDonald criteria for the use of MRI in diagnosing multiple sclerosis.

The MAGNIMS collaborative research network argued that new data on the application of MRI, as well as improvements in MRI technology, demanded changes to the multiple sclerosis (MS) diagnostic criteria.

The first proposed recommendation is that three or more focal lesions, rather than a single lesion, should be present to diagnose the involvement of the periventricular region and to show disease dissemination in space (Lancet Neurol. 2016 Jan 25. doi: 10.1016/S1474-4422[15]00393-2).

HUNG KUO CHUN/Thinkstock

“A single lesion was deemed not sufficiently specific to determine whether involvement of the periventricular region is due to a demyelinating inflammatory event, and the use of one periventricular lesion for assessing dissemination in space has never been formally validated,” wrote Dr. Massimo Filippi of Vita-Salute San Raffaele University, Milan, and his coauthors.

They also pointed out that incidental periventricular lesions can be found in up to 30% of patients with migraine, and in individuals with other neurologic disorders.

In addition, the group recommended that optic nerve lesions be added to the criteria for dissemination in space.

“Clinical documentation of optic nerve atrophy or pallor, neurophysiological confirmation of optic nerve dysfunction (slowed conduction), or imaging features of clinically silent optic nerve inflammation (MRI lesions or retinal nerve fiber layer thinning) support dissemination in space and, in patients without concurrent visual symptoms, dissemination in time.”

According to the new recommendations, disease dissemination in space can be shown by the involvement of at least two areas from a list of five possibilities: three or more periventricular lesions, one or more infratentorial lesions, one or more spinal cord lesions, one or more optic nerve lesions, or one or more cortical or juxtacortical lesions.

However, the group did not propose any significant changes to the criteria for dissemination in time, other than saying that the presence of nonenhancing black holes should not be considered as a potential alternative criterion to show dissemination in time in adult patients.

The committee also backed the existing recommendations that children aged 11 years or older with nonacute disseminated encephalomyelitis–like presentation should be diagnosed with the same criteria as adults, for dissemination in time and space.

“Several studies have confirmed that the 2010 McDonald criteria perform better than or similar to previously proposed pediatric MS criteria for diagnosis of children with nonacute disseminated encephalomyelitis presentations and pediatric patients older than 11 years, and the consensus group therefore recommend caution when using these criteria in children younger than 11 years,” they wrote.

Other recommendations include that there be no distinction required between symptomatic and asymptomatic MRI lesions for diagnosing dissemination in time or space; that the whole spinal cord be imaged to define dissemination in space, particularly in patients who do not fulfill the brain MRI criteria; and that the same criteria for dissemination in space be used for both primary progressive MS and relapse-onset MS, with cerebrospinal fluid results considered for clinically uncertain cases of primary progressive MS.

The expenses of the workshop where the recommendations were formulated were supported by an unrestricted educational grant from Novartis. The authors of the paper declared grants, consultancies, speaking fees, travel support, and honoraria from numerous pharmaceutical companies, including Novartis.